Infliximab: A new treatment for rheumatoid arthritis

Hospital Medicine

Volumn 62, Issue 3, 2001, Pages 150-152

  Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

COST BENEFIT ANALYSIS; DRUG ANTAGONISM; ECONOMICS; HUMAN; IMMUNOLOGY; PATIENT SELECTION; PHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; HUMANS; PATIENT SELECTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035293368     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2001.62.3.1534     Document Type: Article

References (10)

1. ATTRACT Study Group (1999) Infliximab (chimeric antitumour necrosis factor a monoclonal antibody) v.v placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354: 1932-9
2. Bingham S, Emery P (2000) Resistant rheumatoid arthritis clinics: a necessary development? Rheumatology 39(1 ): 2-5
3. Elliott MJ, Maini RN, Feldmann M et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to TNFot (Remicade) v.v placebo in rheumatoid arthritis. Lancet 344: 1105
4. Emery P, Panayi GS, Sturrock R, Williams BD (1999) Targeted therapies in rheumatoid arthritis: the need for action. Rheumatology 38: 911-12
5. Joosten LA. Helsen MM, Saxne T, Van De Loo FA. Heinegard D, Van Den Berg WB (1999) 1L-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis whereas TNFalpha blockade only ameliorates joint inflammation. ./ Immunol 163(9): 5049-55
6. Kobelt G, Eberhard! K, Jonsson L, Jonsson B (1999) Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 42: 347-56
7. Lipsky PE, Van der Heijde D, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N EnglJ Med343(22): 1594-602
8. Mclntosh E (1996) The cost of rheumatoid arthritis. Br J Rheumatol 35: 781-90
9. Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552-63
10. Yelin E, Wanke L (1999) An assessment of the annual longterm direct costs of rheumatoid arthritis. Arthritis Rheum 42:1209-18